Table 2.
Effects of sakuranetin treatment on cytokine release in lung homogenate quantified by elisa (Bioplex)
| Control (pg mL−1) | OVA (pg mL−1) | OVA + SK (pg mL−1) | OVA + DX (pg mL−1) | |
|---|---|---|---|---|
| RANTES | 10.82 ± 1.74 | 24.70 ± 5.55* | 9.38 ± 1.39 | 3.81 ± 0.45 |
| IL-5 | 1.61 ± 0.34 | 22.60 ± 8.28* | 5.61 ± 1.45 | 1.70 ± 0.37 |
| IL-4 | 3.51 ± 0.52 | 7.57 ± 0.12** | 6.64 ± 0.82 | 2.62 ± 0.73 |
| Eotaxin | 248.87 ± 88.35 | 759.39 ± 107.10* | 436.74 ± 112.78 | 220.56 ± 42.79 |
| IL-10 | 1.73 ± 0.20 | 3.87 ± 2.05 | 2.22 ± 0.70 | 2.50 ± 0.33 |
| TNF-α | 1.97 ± 0.40 | 1.85 ± 0.19 | 1.55 ± 0.46 | 1.25 ± 0.15 |
| IFN-γ | 4.24 ± 0.87 | 5.37 ± 1.98 | 4.76 ± 0.90 | 2.48 ± 0.26 |
| GM-CSF | 5.27 ± 0.61 | 9.70 ± 1.58 | 6.70 ± 0.83 | 5.77 ± 0.60 |
Data are presented as mean ± SE.
*
P < 0.05 compared with others experimental groups;
**
P < 0.05 compared only with control and OVA + DX groups.